Thursday, December 6, 2018
Edwards Lifesciences sees FY19 revenue growth of 11%-15%
Outlook coming from the company’s Analyst Day presentation slides yesterday. The company also forecast global TAVR, or Transcatheter aortic valve replacement, opportunity beyond 2024 reaching $7B from $3.5B in 2018.
https://thefly.com/landingPageNews.php?id=2832915
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.